Earnings Releases·Nov 5, 2026, 7:09 AM ET

Climb Bio — Third Quarter 2026 Earnings Summary

Cash, cash equivalents, and marketable securities increased to $227.6 million as of September 30, 2026, from $160.7 million at year-end 2025, with total operating expenses for the nine months ended September 30, 2026, declining to $47.5 million from $48.6 million in the prior period.
Net loss narrowed to $14.6 million ($0.18 per share) for the three months ended September 30, 2026, compared to $12.9 million ($0.19 per share) in 2025, and $41.8 million ($0.56 per share) for the nine-month period versus $42.3 million ($0.63 per share) previously.
The Company expects its current cash balance to fund operations into the second half of 2028, with initial NAVIGATE-2 Phase 2 data for CLYM116 and additional PrisMN Phase 2 cohort data anticipated in the first half of 2027.
Strategic progress includes the initiation of the NAVIGATE-2 Phase 2 trial for CLYM116 in IgA nephropathy, pending regulatory feedback for a global Phase 3 trial in 2027, and an exclusive license agreement for technology transfer in China with Beijing Mabworks Biotech Co. Ltd.